Sunday, June 12, 2005


Exhibit HallAn interesting report we heard focused on another new drug that we'll likely see in the next 6 months to a year. The drug is called Rimonanbant and is made by sanofi-aventis. It appears to be really good for weight loss and for many cardiovascular disease risk factors.

In the study we heard about, people with diabetes were given the drug or given a placebo. Those who were given the drug lost an average of 12 pounds, their A1C dropped by about .6%, their HDL (good cholesterol) went up , triglycerides went down. Side effects were not very different between the control group and the treated group. So it looks like a promising drug for reducing a lot of the cardiovascular risk factors that are so prevalent in people with diabetes.

So now we have two experimental drugs that will hopefully soon be licensed. Muraglitizar, a new class of agents for lowering blood glucose and Rimonanbant. If all goes well both drugs could be approved and available for use in the next year or so.

But the real buzz in the halls is still the follow-up of the DCCT and the incredible reduction of cardiovascular disease. Just a startling result.